Clinical trials Below are current clinical trials.18 studies in Allergic Diseases (open studies only). Filter this list of studies by location, status and more. Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of Sulfonamide Allergy Rochester, Minn. The aim of this study is to study the efficacy and safety of our short and long one-day protocols for TMP-SMX graded administration in hematologic malignancy, hematopoietic stem cell transplant, and solid organ transplant patients. New Mast Cell Lines from Patients with Systemic Mastocytosis Rochester, Minn. The purpose of this study is to attempt to establish new mast cell lines from patients with systemic mastocytosis using peripheral blood and/or bone marrow. Analysis of Group 2 Innate Lymphoid Cells in Peripheral Blood Rochester, Minn. The primary objective of this study is to investigate the contribution of group 2 innate lymphoid cells (ILC2s) to the immunologic mechanisms of chronic airway diseases. Prognostic Risk Evaluation for Hypereosinophilic Syndrome (HES) and Idiopathic Hypereosinophilia (IHE) and the Role of Next-generation Sequencing Rochester, Minn. The purpose of this study is to: To identify predictors of inferior overall survival in HES/IHE patients including molecular parameters using next-generation sequencing performed at the point of clinical care To apply the previously proposed prognostic model that included myeloid-relevant gene mutations to identify high-risk HES/IHE patients for closer monitoring A Study to Evaluate the Effectiveness and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES) Rochester, Minn. This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study comprises 2 distinct periods (together defined as the 'main study'): A 24-week, DB treatment period, during which patients will be randomised to receive either benralizumab or placebo, in addition to prior stable HES background therapy, and an open-label (OLE) treatment period, during which all patients will receive benralizumab. The primary database lock (DBL) will occur when at least 47 patients have had their first HES worsening/flare event and all randomised patients have been followed up for the 24-week DB treatment period. The target patient population is male and female patients 12 years of age and older with symptomatic active HES. Approximately 120 eligible patients will be randomised at a 1:1 ratio to receive either benralizumab or matching placebo. A Study of the Effects of Preterm Birth on Lung Disease and Innate Immunity Later in Life Rochester, Minn. The primary purpose of this study is to investigate the cytokine responses of blood ILC2s from preterm children by collecting peripheral blood at age 5-10 years from children born either preterm or at term, and to analyze the functions of their circulating ILC2s in vitro. A Study to Evaluate the Effect of Medical Intervention on Sinonasal Inflammation in Patients with Chronic Sinusitis, Nasal Polyps and Positive Sinus Culture Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to compare change in SNOT-22 score in patients who received medication therapy such as oral antibiotics, topical antibiotics, oral corticosteroids, topical corticosteroids, leukotriene receptor antagonist, and interleukin 5 receptor antagonist following endoscopic sinus surgery versus control in patient with chronic sinusitis with nasal polyps and a positive culture. Factors Contributing to Underutilization of Epinephrine for Allergy Anaphylaxis Jacksonville, Fla., Rochester, Minn. The purpose of this study is to evaluate the rate of compliance for having an emergency epinephrine autoinjector readily accessible in adults with allergies, and to determine factors that negatively influence adults with allergies for having an emergency epinephrine autoinjector readily accessible. Pagination Clinical studies PrevPrevious Page Go to page 11 Go to page 22 Request an appointment Specialty groupsResearch June 04, 2020 Share on: FacebookTwitter Allergic DiseasesSectionsOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsClinical trialsResearchCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an AppointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsClinical trialsResearchCosts & insuranceNews from Mayo ClinicReferrals ORG-20485266 Medical Departments & Centers Allergic Diseases